Human-Relevant Non-Animal Methodologies (NAMs)
Specialised Models Series: **Immune & Infectious Disease**

Vaccine Development Platform

Reference 2.4 in Full Scope Roadmap

Version 1.0 | June 2026 Edition
Compiled for the Alliance for Cruelty Free Science by Georgina Rednall
Prepared for Academic Leadership, Animal Welfare & Ethical Review Bodies (AWERB), and Principal Investigators

Legal & Scientific Imperative for Universities

Section 2A of the *Animals (Scientific Procedures) Act 1986* imposes a statutory duty on the Secretary of State to ensure compliance with the principles of replacement, reduction, and refinement. The principle of replacement requires that, wherever a scientifically satisfactory method or testing strategy not entailing the use of protected animals is available, it must be used to replace the use of a regulated procedure.

Traditional vaccine development workflows rely heavily on legacy *in vivo* models—such as non-human primates and mice for neutralising antibody titers and pathogen challenge studies. These legacy platforms suffer from severe translational limitations due to fundamental species differences. These limitations are evident in the following critical disparities:

Innate Immune Signalling Divergence: Discrepancies in Toll-like receptor (TLR) expression and activation pathways between humans and rodents mean that adjuvanticity—the ability to boost immune responses—is often incorrectly predicted in animal models.

Antibody and B-cell Function Mismatch: Differences in somatic hypermutation rates, antibody isotype functions, and B-cell maturation processes frequently cause vaccine formulations that appear promising in animals to fail in human clinical trials due to inadequate potency or altered specificity.

Host-Pathogen Restriction Factors: The mechanisms by which human hosts restrict viral or bacterial replication are highly specific. Rodent models lack the human-specific restriction factors and cellular receptors necessary to accurately model the protective efficacy of novel vaccine candidates.

Severity of Challenge Studies: Pathogen challenge studies in animals often involve high-containment, high-severity procedures that inflict significant suffering and morbidity, providing a major ethical and regulatory impetus to prioritise replacement.

Accelerating the adoption of human-relevant Non-Animal Methodologies (NAMs)—such as microfluidic biomimetic lymph nodes, engineered human mucosal barriers, and predictive *in silico* computational antigen-mapping—is therefore both a scientific imperative for accelerating pandemic preparedness and a legal mandate for UK universities.

Landmark Regulatory & Scientific Momentum

Significant progress has been made in the development and application of human-relevant vaccine development NAMs:

- **Biomimetic Lymph Node-on-Chip:** Faithfully recapitulates human germinal centre dynamics, B-cell clonal expansion, somatic hypermutation, and antibody class-switching under physiological fluid flow.
- **Human Mucosal & Airway Tissue Barriers:** Differentiate patient-derived or primary stem cells into air-liquid interface (ALI) lung, nasal, or gut barriers to model real-world pathogen entry, mucosal immunity (IgA production), and localised adjuvant responses.
- **In Silico Immune Profiling & AI Antigen Mapping:** Leverage structural biology algorithms and multi-omics pipelines to forecast epitope binding, simulate population-wide HLA diversity responses, and design targeted vaccine candidates prior to wet-lab fabrication.

Core Specialised Vaccine Platforms



Figure 1: Core Specialised Vaccine Development Platforms — Biomimetic lymph node-on-chip displaying cellular migration and T/B cell zones *(left)*, multi-lineage mucosal air-liquid interface tissue platform capturing primary pathogen entry and innate restriction kinetics *(centre)*, and high-throughput microfluidic screening array monitoring multi-organ cytokine cascades and systemic immune cell trafficking *(right)*.

Table 1: Biological & Tissue-Engineered (In Vitro) Platforms

Platform / Model	Description	Key Applications	Benefits for Universities & 3Rs
Biomimetic Lymph Node-on-Chip	Microfluidic platforms that assemble human primary B and T lymphocytes with follicular dendritic cells under physiological shear flow to form active germinal centres.	Evaluation of vaccine-induced antigen presentation, B-cell clonal selection, somatic hypermutation, and high-affinity IgG antibody generation.	High human relevance for capturing functional humoral responses; provides robust alternatives to non-human primate adjuvant screening.
Air-Liquid Interface (ALI) Mucosal Barriers	Differentiated primary human epithelial constructs (nasal, bronchial, or intestinal) co-cultured with resident dendritic cells and macrophages.	Modelling mucosal delivery vectors, innate immune barrier restrictions, secretory IgA dynamics, and live pathogen challenge assays.	Enables functional, localized evaluation of inhaled or oral formulations without invasive rodent challenge models.
High-Throughput Human Organoid Arrays	Multicellular organoids derived from human tonsil or peripheral blood mononuclear cells (PBMCs) arranged in automated fluidic screening microplates.	Rapid screening of diverse adjuvant candidates, dose-escalation toxicity profiles, and tracking early chemokine secretion profiles.	Accelerates the pre-clinical filtering of vaccine formulations, significantly reducing the number of candidate variations that reach in vivo evaluation.

Cross-Cutting & Enabling Platforms for Vaccine Research

These platforms support multiple infectious disease and prophylactic design areas and are widely applicable across various viral, bacterial, and parasitic target pipelines, adjuvant formulation screening, and public health pandemic response initiatives. While specialised models focus on localised mucosal entry or secondary lymphoid tissue niches, these enabling platforms are essential for validating high-maturity NAMs and ensuring they meet the high standards required for regulatory-accepted, "fit-for-purpose" research.



Figure 2: Cross-Cutting & Enabling Platforms for Vaccine Research — AI-driven computational antigen mapping targeting epitope-HLA binding profiles *(left)*, mechanistic cellular simulation models tracking clonal selection over time *(centre)*, and safety screening frameworks predictive of systemic reactogenicity or adverse autoimmune events post-immunisation *(right)*.

Table 2: Genetic, Computational & Framework-Driven Platforms

Platform / Model	Description	Key Applications	Benefits for Universities & 3Rs
AI-Driven Antigen Epitope Mapping	Deep learning algorithms trained on human immuno-peptidomics data to project structural molecular structures of optimal target antigens.	Predicting antigen-HLA binding affinities across hyper-diverse human populations and optimising structural vaccine stabilisation.	Directly circumvents animal-based serum screening pipelines; provides definitive digital evidence for antigen selection.
In Silico Whole-Immune System Digital Twins	Computational fluid and kinetic models that simulate multi-organ lymphocyte trafficking, germinal center dynamics, and affinity maturation.	Forecasting long-term memory cell retention, secondary booster timeline requirements, and kinetic population variances.	Holistic systems biology tool; ideal for guiding experimental parameters and replacing multi-year primate longitudinal studies.
AOP-Integrated Adverse Event Screeners	Adverse Outcome Pathway (AOP) digital networks linking molecular initiation events (e.g., TLR activation) to clinical signs of systemic reactogenicity.	Early screening for vaccine-induced hyper-inflammation, antibody-dependent enhancement (ADE), or unexpected auto-inflammatory triggers.	Aligns perfectly with Home Office / ASRU standards for regulatory acceptance and "fit-for-purpose" safety profiling.

Regulatory Software & Strategy Frameworks

Regulatory acceptance of NAMs—referred to as "fit-for-purpose qualification"—is not a one-size-fits-all process. Researchers should utilise the following frameworks to ensure their computational and biological strategies align with the *Animals (Scientific Procedures) Act 1986* and industry best practices:

- **Context of Use (COU) Documentation:** Before deploying models, clearly define the specific scientific question the model is intended to address. This is critical for demonstrating that the NAM is reliable and suitable for its intended regulatory purpose.
- **Technical Characterisation:** Maintain comprehensive Standard Operating Procedures (SOPs) and study plans for both the biological NAM and any software used to analyse its output. This transparency is vital for successful project licence applications.
- **Early Regulatory Engagement:** Leverage institutional or external regulatory support to track "fit-for-purpose" milestones. Early engagement with the Home Office/ASRU is strongly encouraged to test the acceptability of a computational or NAM-based approach before full project submission.
- **Weight-of-Evidence (WoE) Frameworks:** Use integrated digital dashboards to aggregate data from both *in vitro* (NAM) and *in silico* (computational) sources. Building a strong "weight-of-evidence" argument is the most effective way to strengthen Replacement justifications when moving away from traditional animal models.

Skills, Training, and Capacity Building

Successful adoption of high-maturity Non-Animal Methodologies (NAMs) requires a strategic shift in workforce development. To ensure the long-term success of the platforms outlined in this series, universities should prioritise the following training initiatives to build institutional capacity:

- **Integrated Vaccinology & Data Science:** Training programmes should bridge the gap between bench-top cellular biology, fluidic microengineering, and complex multi-omics data analysis. Researchers require dual proficiency in maintaining long-term lymph node models and leveraging the computational pipelines necessary to interpret high-throughput antibody repertoires.
- **Regulatory Competency:** Staff should receive formal training on "Fit-for-Purpose" qualification and the specific regulatory expectations of the Home Office/ASRU. This includes understanding how to document evidence for the 3Rs within formal project licence applications to ensure they meet legal standards.
- **Technological Literacy:** Skills in microfluidic device troubleshooting, primary stem-cell tissue differentiation, and AI-driven structural epitope modelling are increasingly critical for modern vaccine development. Universities should facilitate internal workshops or establish external partnerships to provide PhD students and postdoctoral fellows with hands-on experience in these specialised tools.
- **Ethics & Translation:** Education should focus on the scientific imperative of human-relevant research, emphasising why NAMs provide more predictive insights for clinical outcomes than traditional rodent or non-human primate models. This fosters a culture of excellence and ethical research design that is fully aligned with modern international standards.

Table 3: Skills • Training, and Capacity Building

Capability Domain	Focus Area	Impact on 3Rs/Replacement
Technical	Microfluidic assembly & ALI maintenance	Direct replacement of primate/rodent challenge models
Bioinformatics	Computational antigen-mapping & in silico screening	Bypasses large-scale animal immunisation protocols
Regulatory	ASPA 1986 Compliance & AWERB	Facilitates transition from high-severity animal challenge studies
Computational	PBPK & immune-response modelling	Eliminates invasive sampling in animal vaccine trials

Strategic Note: This investment in human expertise is a key component of a robust, future-proof institutional roadmap, demonstrating to regulators that the institution is committed to the safe and effective operation of high-maturity NAMs.

Clinical Translation Case Studies

Case Study 1: Human Lymph Node-on-Chip Outperforming Rodent Adjuvant Assays

- **Background:** Traditional vaccine screening relies on mouse models to test novel adjuvant formulations. However, adjuvants that activate murine toll-like receptors often fail to trigger equivalent downstream pathways in human dendritic cells and lymphocytes.

- **The Paradigm Shift:** Using a microfluidic human lymph node-on-chip containing primary human lymphocytes, an academic-industry consortium successfully mapped the human-specific reactogenicity of a panel of novel lipid nanoparticles (LNPs), bypassing rodent cohorts completely.

- **The Methodology:** Researchers used the microfluidic platform to measure real-time human B cell activation, somatic hypermutation markers, and cytokine profiles (such as IFN-γ and IL-2). The human chip correctly predicted clinical immunogenicity trends where parallel rodent trials had yielded false-positive indicators.

- **University & Legal Takeaway:** These results offer compelling non-animal evidence to support Project Licence applications, illustrating a clear methodology for replacing animal models under ASPA 1986 requirements.

Case Study 2: AI Antigen Selection Entering First-in-Human Clinical Evaluation

Background: Traditional development of universal influenza and pan-coronavirus candidates requires iteratively immunising hundreds of animals to map cross-reactive antibody responses against shifting viral variants.

- **The Paradigm Shift:** A university spin-out combined deep learning structural epitope mapping with in vitro air-liquid interface (ALI) lung models to design and evaluate a completely synthetic multi-epitope vaccine construct without any prior animal immunisations.

- **The Methodology:** Computational models analysed thousands of viral structural variants to select highly conserved, immunogenic target sequences. The optimised design was directly tested on human respiratory tissue models to ensure robust innate antigen processing, advancing the candidate straight to First-in-Human clinical trial design.

- **University & Legal Takeaway:** Demonstrates that high-fidelity in silico tools can serve as a primary screen, providing solid legal justification to the Home Office that animal testing was completely unnecessary for this development pipeline.

Executive Summary & Compliance Dashboard

Executive Summary

Traditional vaccine development, heavily reliant on non-human primate and rodent challenge models, suffers from significant translational failure due to species-specific differences in TLR expression, antibody function, and immune restriction factors. This roadmap outlines a transition to high-fidelity, human-relevant NAMs (biomimetic lymph node-on-chip, ALI mucosal barriers, and predictive *in silico* antigen-mapping), moving toward a research paradigm that is more accurate, ethically sound, and fully aligned with the ASPA 1986 mandate to transition away from regulated animal procedures.

Compliance Dashboard

Focus Area	Primary Animal Model	NAM Replacement Technology	ASPA 1986 Status
Vaccine Development	Non-human primate / Rodent challenge models	Biomimetic Lymph Node & ALI Mucosal Platforms	High

See Appendix: Animal-Free Matrix for the long term strategic implementation roadmap

Maturity Matrix

Phase 1 (Exploratory): Audit current animal use in vaccine efficacy and challenge studies.

Phase 2 (Pilot): Integrate lymph node-on-chip and ALI barrier culture protocols into research pipelines.

Phase 3 (Integration): Implement multi-organ immune-metabolic MPS to model systemic response to vaccination.

Phase 4 (Standardisation): Replace 100% of high-severity animal challenge and neutralisation assays with qualified human-relevant NAMs.

Final Compliance Statement

All proposed models satisfy the Section 2A statutory duty of ASPA 1986. By adopting these methodologies, the institution positions itself at the forefront of the global transition toward human-centric, cruelty-free medical science.

Integration Context: Roadmap Conclusion

The modules detailed in this roadmap—from the fundamental immunology (2.1) and infectious disease modelling (2.2) to the cancer immunotherapy (2.3) and vaccine development platforms explored in this section (2.4)—demonstrate that replacement is not a siloed scientific exercise but an integrated institutional strategy. By mapping these specialised NAM-based immune platforms into a unified regulatory framework, the institution moves decisively toward a standardised, human-centric research paradigm. This systemic integration is the essential prerequisite for fulfilling the ASPA 1986 statutory duty, ensuring all research is scientifically accurate, ethically aligned, and regulatory compliant.

Appendix: Animal-Free Maturity Matrix

Vaccine Development & Immune Modelling Roadmap

This matrix maps the progression of vaccine research platforms from legacy *in vivo* reliance to human-relevant, animal-free methodologies.

Phase	Maturity Level	Focus Area	Key NAM Integration & Milestone
Phase 1	Exploratory	Baseline Assessment	In silico antigen-epitope mapping and HLA-binding prediction against population-wide cohorts.
Phase 2	Pilot	Technical Validation	Deployment of Lymph Node-on-Chip systems for adjuvant screening and dose-escalation toxicity profiles.
Phase 3	Integration	Operational Capability	Integration of Air-Liquid Interface (ALI) mucosal models to evaluate vaccine-induced secretory IgA dynamics.
Phase 4	Standardisation	Full Replacement	Full reliance on Multi-Organ "Digital Twins" and high-throughput organoid arrays for final pre-clinical efficacy and safety profiling.

Implementation & Compliance Framework

ASPA 1986 Compliance: This roadmap directly supports the institutional duty to replace regulated animal procedures with human-relevant methods. The goal is to move beyond "one-size-fits-all" legacy models toward predictive, human-specific safety profiles.

Weight-of-Evidence (WoE) Dossier: To justify the cessation of non-human primate or rodent challenge studies, researchers must aggregate data from multi-organ kinetic simulations and epitope-mapping outputs.

Regulatory Alignment: Use of these platforms—particularly the Lymph Node-on-Chip and ALI models—is designed to align with ASRU and Home Office expectations for "fit-for-purpose" safety profiling.

Strategic Note: Transitioning to these platforms significantly reduces the reliance on high-severity animal challenge models, thereby lowering institutional ethical risk and shortening the pre-clinical filtering pipeline.